{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-013022","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2022-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.316777+00:00","generated_at":"2026-06-26T12:58:10.107397+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ARCA biopharma's rNAPc2 fails to meet primary endpoint in Phase 2b COVID-19 trial","bullets":["Pooled rNAPc2 reduced D-dimer 16.8% vs heparin 11.2% (P=0.47), missing statistical significance.","Per-protocol analysis: rNAPc2 reduced D-dimer 28.7% vs heparin increase 1.1% (P=0.33).","In WHO Severe patients, heparin D-dimer increased 29.0% (P=0.022); rNAPc2 changed 25.9% (P=0.16).","Thrombotic events: 9 in heparin group vs 6 in rNAPc2; hazard ratio for recovery 0.88, neither significant.","Company will not pursue direct superiority trial vs heparin for COVID-19; evaluating partnering and strategic options."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-013022","json":"https://secwatch.observer/filing/0001564590-22-013022.json","markdown":"https://secwatch.observer/filing/0001564590-22-013022.md","text":"https://secwatch.observer/filing/0001564590-22-013022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000156459022013022/0001564590-22-013022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000156459022013022/abio-8k_20220331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T12:58:10.107397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}